article Open AccessTop 1% cited
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Archives of Neurology · 2009 · Vol. 66(3) · pp. 382–9
Tero Tapiola✉(University of Eastern Finland)Irina Alafuzoff(University of Eastern Finland)Sanna‐Kaisa Herukka(University of Eastern Finland)Laura Parkkinen(University of Eastern Finland)Päivi Hartikainen(University of Eastern Finland)Hilkka Soininen(Kuopio University Hospital)Tuula Pirttilä(University of Eastern Finland)
Abstract
Cerebrospinal fluid Abeta42 and tau proteins are biomarkers of AD-associated pathologic changes in the brain. The combination of abnormally low CSF Abeta42 level and abnormally high CSF tau level predicted the presence of AD pathologic features with high accuracy. This combination assay may be helpful in diagnosing the presence of AD pathologic changes in the brain.
Alzheimer's disease research and treatmentsDementia and Cognitive Impairment ResearchAdvanced Neuroimaging Techniques and ApplicationsCerebrospinal fluidPathologySenile plaquesTau proteinMedicineAlzheimer's diseaseNeurologyBiomarkerDementiaAmyloid (mycology)
MeSH terms
AgedAged, 80 and overAlzheimer DiseaseApolipoproteins EBrainCross-Sectional StudiesDementiaFemaleHumansImmunoassayMaleNervous System DiseasesPeptide FragmentsRetrospective StudiesROC Curve
Citations
892
FWCI
26.32
field-weighted impact
References
29
Percentile
100%
vs. same field & year
Citations per year
Cited by
Human apoE Isoforms Differentially Regulate Brain Amyloid-β Peptide Clearance
Science Translational Medicine · 2011 · 1,172 citations
A/T/N: An unbiased descriptive classification scheme for Alzheimer disease biomarkers
Neurology · 2016 · 1,813 citations
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
The Lancet Neurology · 2014 · 3,256 citations
CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis
The Lancet Neurology · 2016 · 2,045 citations
Revising the definition of Alzheimer's disease: a new lexicon
The Lancet Neurology · 2010 · 1,837 citations
Current state of Alzheimer’s fluid biomarkers
Acta Neuropathologica · 2018 · 514 citations
Emerging Roles of Exosomes in Normal and Pathological Conditions: New Insights for Diagnosis and Therapeutic Applications
Frontiers in Immunology · 2015 · 599 citations
Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers
The Lancet Neurology · 2013 · 4,351 citations
References
Frontotemporal lobar degeneration
Neurology · 1998 · 5,047 citations
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ <sub>42</sub> in humans
Annals of Neurology · 2005 · 1,247 citations
Staging of Alzheimer disease-associated neurofibrillary pathology using paraffin sections and immunocytochemistry
Acta Neuropathologica · 2006 · 3,202 citations
Diagnosis and management of dementia with Lewy bodies
Neurology · 2005 · 5,038 citations
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
The Lancet Neurology · 2007 · 4,360 citations
CSF markers for incipient Alzheimer's disease
The Lancet Neurology · 2003 · 1,290 citations
The Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Neurology · 1991 · 5,023 citations
Clinical diagnosis of Alzheimer's disease
Neurology · 1984 · 27,910 citations
Related articles
Cerebrospinal Fluid β-Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain
Archives of Neurology · 2009 · 892 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.